Combination Therapy with Bevacizumab and a CCR2 Inhibitor for Human Ovarian Cancer: An in Vivo Validation Study – ICReDD: Institute for Chemical Reaction Design and Discovery, Hokkaido University (WPI-ICReDD)

Publications

Combination Therapy with Bevacizumab and a CCR2 Inhibitor for Human Ovarian Cancer: An in Vivo Validation Study

Mar 16, 2023